VCM
JANX icon

Versant Capital Management’s Janux Therapeutics JANX Stock Holding History

Versant Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.2K Buy
2,615
+784
+43% +$11.4K ﹤0.01% 1515
2026
Q1 		$25.5K Buy
+1,831
New +$25.1K ﹤0.01% 1684

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Versant Capital Management's JANX Position: Q2 2026 in Review

Versant Capital Management increased its Janux Therapeutics (JANX) stake by 43% in Q2 2026, buying an estimated $11.4K and bringing the position to 2,615 shares worth $40.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1515.

Versant Capital Management first reported a position in JANX in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Versant Capital Management held 2,615 shares of Janux Therapeutics worth $40.2K as of Q2 2026.
  • Versant Capital Management bought 784 Janux Therapeutics shares in Q2 2026, an estimated $11.4K.
  • Janux Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1515 holding.
  • Versant Capital Management first reported a position in Janux Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.